These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 29882016)

  • 1. Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.
    Rodon J; Pérez-Fidalgo A; Krop IE; Burris H; Guerrero-Zotano A; Britten CD; Becerra C; Schellens J; Richards DA; Schuler M; Abu-Khalaf M; Johnson FM; Ranson M; Edenfield J; Silva AP; Hackl W; Quadt C; Demanse D; Duval V; Baselga J
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):285-298. PubMed ID: 29882016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors.
    Bendell JC; Kurkjian C; Infante JR; Bauer TM; Burris HA; Greco FA; Shih KC; Thompson DS; Lane CM; Finney LH; Jones SF
    Invest New Drugs; 2015 Apr; 33(2):463-71. PubMed ID: 25707361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies.
    Wise-Draper TM; Moorthy G; Salkeni MA; Karim NA; Thomas HE; Mercer CA; Beg MS; O'Gara S; Olowokure O; Fathallah H; Kozma SC; Thomas G; Rixe O; Desai P; Morris JC
    Target Oncol; 2017 Jun; 12(3):323-332. PubMed ID: 28357727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors.
    Toyoda M; Watanabe K; Amagasaki T; Natsume K; Takeuchi H; Quadt C; Shirao K; Minami H
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):289-299. PubMed ID: 30446785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma.
    Carlo MI; Molina AM; Lakhman Y; Patil S; Woo K; DeLuca J; Lee CH; Hsieh JJ; Feldman DR; Motzer RJ; Voss MH
    Oncologist; 2016 Jul; 21(7):787-8. PubMed ID: 27286790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia.
    Lang F; Wunderle L; Badura S; Schleyer E; Brüggemann M; Serve H; Schnittger S; Gökbuget N; Pfeifer H; Wagner S; Ashelford K; Bug G; Ottmann OG
    BMC Pharmacol Toxicol; 2020 Sep; 21(1):70. PubMed ID: 32993794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer.
    Wei XX; Hsieh AC; Kim W; Friedlander T; Lin AM; Louttit M; Ryan CJ
    Oncologist; 2017 May; 22(5):503-e43. PubMed ID: 28314838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.
    Saura C; Bendell J; Jerusalem G; Su S; Ru Q; De Buck S; Mills D; Ruquet S; Bosch A; Urruticoechea A; Beck JT; Di Tomaso E; Sternberg DW; Massacesi C; Hirawat S; Dirix L; Baselga J
    Clin Cancer Res; 2014 Apr; 20(7):1935-45. PubMed ID: 24470511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.
    Markman B; Tabernero J; Krop I; Shapiro GI; Siu L; Chen LC; Mita M; Melendez Cuero M; Stutvoet S; Birle D; Anak Ö; Hackl W; Baselga J
    Ann Oncol; 2012 Sep; 23(9):2399-2408. PubMed ID: 22357447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
    Gandhi L; Bahleda R; Tolaney SM; Kwak EL; Cleary JM; Pandya SS; Hollebecque A; Abbas R; Ananthakrishnan R; Berkenblit A; Krygowski M; Liang Y; Turnbull KW; Shapiro GI; Soria JC
    J Clin Oncol; 2014 Jan; 32(2):68-75. PubMed ID: 24323026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
    Guerin M; Rezai K; Isambert N; Campone M; Autret A; Pakradouni J; Provansal M; Camerlo J; Sabatier R; Bertucci F; Charafe-Jauffret E; Hervieu A; Extra JM; Viens P; Lokiec F; Boher JM; Gonçalves A
    Eur J Cancer; 2017 Nov; 86():28-36. PubMed ID: 28950146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.
    Massard C; Chi KN; Castellano D; de Bono J; Gravis G; Dirix L; Machiels JP; Mita A; Mellado B; Turri S; Maier J; Csonka D; Chakravartty A; Fizazi K
    Eur J Cancer; 2017 May; 76():36-44. PubMed ID: 28282611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
    Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
    BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer.
    Chen L; Jin T; Zhu K; Piao Y; Quan T; Quan C; Lin Z
    Oncotarget; 2017 Feb; 8(7):11937-11949. PubMed ID: 28060760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
    Murthy R; Borges VF; Conlin A; Chaves J; Chamberlain M; Gray T; Vo A; Hamilton E
    Lancet Oncol; 2018 Jul; 19(7):880-888. PubMed ID: 29804905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model.
    Matsushima M; Kikuchi E; Matsumoto K; Hattori S; Takeda T; Kosaka T; Miyajima A; Oya M
    Int J Oncol; 2015 Jul; 47(1):377-83. PubMed ID: 25963317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.
    Fazio N; Buzzoni R; Baudin E; Antonuzzo L; Hubner RA; Lahner H; DE Herder WW; Raderer M; Teulé A; Capdevila J; Libutti SK; Kulke MH; Shah M; Dey D; Turri S; Aimone P; Massacesi C; Verslype C
    Anticancer Res; 2016 Feb; 36(2):713-9. PubMed ID: 26851029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
    Shapiro GI; LoRusso P; Cho DC; Musib L; Yan Y; Wongchenko M; Chang I; Patel P; Chan IT; Sanabria-Bohorquez S; Meng RD; Bendell JC
    Invest New Drugs; 2021 Feb; 39(1):163-174. PubMed ID: 32737717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
    Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
    J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.